Report Details

Oligonucleotide Therapy-based Drug Market, Global Outlook and Forecast 2023-2029

ID : PRR-421264
Date : 2023-11-23
Pages : 146
Industry : Pharmaceutical and Healthcare

This research report provides a comprehensive analysis of the Oligonucleotide Therapy-based Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Oligonucleotide Therapy-based Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Oligonucleotide Therapy-based Drug, challenges faced by the industry, and potential opportunities for market players.
The global Oligonucleotide Therapy-based Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Oligonucleotide Therapy-based Drug market presents opportunities for various stakeholders, including Neuromuscular Diseases, hATTR. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Oligonucleotide Therapy-based Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global Oligonucleotide Therapy-based Drug market was valued at US$ 60320 million in 2022 and is projected to reach US$ 14820 million by 2029, at a CAGR of 3.9% during the forecast period.
The Oligonucleotide Drug Delivery Market is driven by the rapid advancement in oligonucleotide-based therapies, including antisense, siRNA, and aptamer-based drugs, which hold immense potential for treating various genetic and rare diseases. These therapies rely on oligonucleotides to modulate gene expression, inhibit specific targets, or diagnose genetic disorders. As the understanding of genetic mechanisms and precision medicine continues to evolve, the demand for efficient and targeted delivery systems for oligonucleotide drugs grows. Innovations in drug delivery technologies, such as lipid nanoparticles and conjugates, as well as the expansion of oligonucleotide drug pipelines, further contribute to market expansion. However, a significant challenge for this market is the need to address the complexity of drug delivery, including overcoming biological barriers, minimizing off-target effects, and ensuring long-term safety and efficacy. Overcoming delivery hurdles, optimizing pharmacokinetics, and navigating regulatory pathways are ongoing challenges. Additionally, the market faces competition from traditional drug therapies, and the need for continuous research and development to enhance the delivery efficiency and patient acceptance of oligonucleotide drugs. Striking a balance between providing efficient and precise oligonucleotide drug delivery solutions while addressing safety and regulatory considerations is crucial for the continued growth of the Oligonucleotide Drug Delivery Market.
Key Features:
The research report on the Oligonucleotide Therapy-based Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Oligonucleotide Therapy-based Drug market.
Market Overview: The report provides a comprehensive overview of the Oligonucleotide Therapy-based Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type e.g., Antisense Oligonucleotides ASO, siRNA, region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Oligonucleotide Therapy-based Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Oligonucleotide Therapy-based Drug markets trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Oligonucleotide Therapy-based Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Oligonucleotide Therapy-based Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Oligonucleotide Therapy-based Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Oligonucleotide Therapy-based Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Oligonucleotide Therapy-based Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Oligonucleotide Therapy-based Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Oligonucleotide Therapy-based Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Antisense Oligonucleotides ASO
siRNA
mRNA
Market segment by Application
Neuromuscular Diseases
hATTR
COVID-19
Other
Global Oligonucleotide Therapy-based Drug Market Segment Percentages, By Region and Country, 2022 %
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Biogen
Nippon Shinyaku
Sobi
Novartis
BioNTech
Pfizer
Moderna Therapeutics
Jazz Pharmaceuticals
CureVac
Regulus Therapeutics
ProQR
Secarna
MiNA Therapeutics
Sylentis
Arrowhead
Silence Therapeutics
Dicerna
Outline of Major Chapters:
Chapter 1: Introduces the definition of Oligonucleotide Therapy-based Drug, market overview.
Chapter 2: Global Oligonucleotide Therapy-based Drug market size in revenue.
Chapter 3: Detailed analysis of Oligonucleotide Therapy-based Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oligonucleotide Therapy-based Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Oligonucleotide Therapy-based Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oligonucleotide Therapy-based Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oligonucleotide Therapy-based Drug Overall Market Size
2.1 Global Oligonucleotide Therapy-based Drug Market Size: 2022 VS 2029
2.2 Global Oligonucleotide Therapy-based Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Oligonucleotide Therapy-based Drug Players in Global Market
3.2 Top Global Oligonucleotide Therapy-based Drug Companies Ranked by Revenue
3.3 Global Oligonucleotide Therapy-based Drug Revenue by Companies
3.4 Top 3 and Top 5 Oligonucleotide Therapy-based Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Oligonucleotide Therapy-based Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oligonucleotide Therapy-based Drug Players in Global Market
3.6.1 List of Global Tier 1 Oligonucleotide Therapy-based Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Oligonucleotide Therapy-based Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Oligonucleotide Therapy-based Drug Market Size Markets, 2022 & 2029
4.1.2 Antisense Oligonucleotides ASO
4.1.3 siRNA
4.1.4 mRNA
4.2 By Type - Global Oligonucleotide Therapy-based Drug Revenue & Forecasts
4.2.1 By Type - Global Oligonucleotide Therapy-based Drug Revenue, 2018-2023
4.2.2 By Type - Global Oligonucleotide Therapy-based Drug Revenue, 2024-2029
4.2.3 By Type - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Oligonucleotide Therapy-based Drug Market Size, 2022 & 2029
5.1.2 Neuromuscular Diseases
5.1.3 hATTR
5.1.4 COVID-19
5.1.5 Other
5.2 By Application - Global Oligonucleotide Therapy-based Drug Revenue & Forecasts
5.2.1 By Application - Global Oligonucleotide Therapy-based Drug Revenue, 2018-2023
5.2.2 By Application - Global Oligonucleotide Therapy-based Drug Revenue, 2024-2029
5.2.3 By Application - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Oligonucleotide Therapy-based Drug Market Size, 2022 & 2029
6.2 By Region - Global Oligonucleotide Therapy-based Drug Revenue & Forecasts
6.2.1 By Region - Global Oligonucleotide Therapy-based Drug Revenue, 2018-2023
6.2.2 By Region - Global Oligonucleotide Therapy-based Drug Revenue, 2024-2029
6.2.3 By Region - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Oligonucleotide Therapy-based Drug Revenue, 2018-2029
6.3.2 US Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.3.3 Canada Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.3.4 Mexico Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Oligonucleotide Therapy-based Drug Revenue, 2018-2029
6.4.2 Germany Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.4.3 France Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.4.4 U.K. Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.4.5 Italy Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.4.6 Russia Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.4.7 Nordic Countries Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.4.8 Benelux Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Oligonucleotide Therapy-based Drug Revenue, 2018-2029
6.5.2 China Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.5.3 Japan Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.5.4 South Korea Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.5.5 Southeast Asia Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.5.6 India Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Oligonucleotide Therapy-based Drug Revenue, 2018-2029
6.6.2 Brazil Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.6.3 Argentina Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Oligonucleotide Therapy-based Drug Revenue, 2018-2029
6.7.2 Turkey Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.7.3 Israel Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Oligonucleotide Therapy-based Drug Market Size, 2018-2029
6.7.5 UAE Oligonucleotide Therapy-based Drug Market Size, 2018-2029
7 Oligonucleotide Therapy-based Drug Companies Profiles
7.1 Sarepta Therapeutics
7.1.1 Sarepta Therapeutics Company Summary
7.1.2 Sarepta Therapeutics Business Overview
7.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
7.1.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.1.5 Sarepta Therapeutics Key News & Latest Developments
7.2 Ionis Pharmaceuticals
7.2.1 Ionis Pharmaceuticals Company Summary
7.2.2 Ionis Pharmaceuticals Business Overview
7.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Major Product Offerings
7.2.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.2.5 Ionis Pharmaceuticals Key News & Latest Developments
7.3 Alnylam
7.3.1 Alnylam Company Summary
7.3.2 Alnylam Business Overview
7.3.3 Alnylam Oligonucleotide Therapy-based Drug Major Product Offerings
7.3.4 Alnylam Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.3.5 Alnylam Key News & Latest Developments
7.4 Biogen
7.4.1 Biogen Company Summary
7.4.2 Biogen Business Overview
7.4.3 Biogen Oligonucleotide Therapy-based Drug Major Product Offerings
7.4.4 Biogen Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.4.5 Biogen Key News & Latest Developments
7.5 Nippon Shinyaku
7.5.1 Nippon Shinyaku Company Summary
7.5.2 Nippon Shinyaku Business Overview
7.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Major Product Offerings
7.5.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.5.5 Nippon Shinyaku Key News & Latest Developments
7.6 Sobi
7.6.1 Sobi Company Summary
7.6.2 Sobi Business Overview
7.6.3 Sobi Oligonucleotide Therapy-based Drug Major Product Offerings
7.6.4 Sobi Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.6.5 Sobi Key News & Latest Developments
7.7 Novartis
7.7.1 Novartis Company Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis Oligonucleotide Therapy-based Drug Major Product Offerings
7.7.4 Novartis Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.7.5 Novartis Key News & Latest Developments
7.8 BioNTech
7.8.1 BioNTech Company Summary
7.8.2 BioNTech Business Overview
7.8.3 BioNTech Oligonucleotide Therapy-based Drug Major Product Offerings
7.8.4 BioNTech Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.8.5 BioNTech Key News & Latest Developments
7.9 Pfizer
7.9.1 Pfizer Company Summary
7.9.2 Pfizer Business Overview
7.9.3 Pfizer Oligonucleotide Therapy-based Drug Major Product Offerings
7.9.4 Pfizer Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.9.5 Pfizer Key News & Latest Developments
7.10 Moderna Therapeutics
7.10.1 Moderna Therapeutics Company Summary
7.10.2 Moderna Therapeutics Business Overview
7.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
7.10.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.10.5 Moderna Therapeutics Key News & Latest Developments
7.11 Jazz Pharmaceuticals
7.11.1 Jazz Pharmaceuticals Company Summary
7.11.2 Jazz Pharmaceuticals Business Overview
7.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Major Product Offerings
7.11.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.11.5 Jazz Pharmaceuticals Key News & Latest Developments
7.12 CureVac
7.12.1 CureVac Company Summary
7.12.2 CureVac Business Overview
7.12.3 CureVac Oligonucleotide Therapy-based Drug Major Product Offerings
7.12.4 CureVac Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.12.5 CureVac Key News & Latest Developments
7.13 Regulus Therapeutics
7.13.1 Regulus Therapeutics Company Summary
7.13.2 Regulus Therapeutics Business Overview
7.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
7.13.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.13.5 Regulus Therapeutics Key News & Latest Developments
7.14 ProQR
7.14.1 ProQR Company Summary
7.14.2 ProQR Business Overview
7.14.3 ProQR Oligonucleotide Therapy-based Drug Major Product Offerings
7.14.4 ProQR Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.14.5 ProQR Key News & Latest Developments
7.15 Secarna
7.15.1 Secarna Company Summary
7.15.2 Secarna Business Overview
7.15.3 Secarna Oligonucleotide Therapy-based Drug Major Product Offerings
7.15.4 Secarna Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.15.5 Secarna Key News & Latest Developments
7.16 MiNA Therapeutics
7.16.1 MiNA Therapeutics Company Summary
7.16.2 MiNA Therapeutics Business Overview
7.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
7.16.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.16.5 MiNA Therapeutics Key News & Latest Developments
7.17 Sylentis
7.17.1 Sylentis Company Summary
7.17.2 Sylentis Business Overview
7.17.3 Sylentis Oligonucleotide Therapy-based Drug Major Product Offerings
7.17.4 Sylentis Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.17.5 Sylentis Key News & Latest Developments
7.18 Arrowhead
7.18.1 Arrowhead Company Summary
7.18.2 Arrowhead Business Overview
7.18.3 Arrowhead Oligonucleotide Therapy-based Drug Major Product Offerings
7.18.4 Arrowhead Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.18.5 Arrowhead Key News & Latest Developments
7.19 Silence Therapeutics
7.19.1 Silence Therapeutics Company Summary
7.19.2 Silence Therapeutics Business Overview
7.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Major Product Offerings
7.19.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.19.5 Silence Therapeutics Key News & Latest Developments
7.20 Dicerna
7.20.1 Dicerna Company Summary
7.20.2 Dicerna Business Overview
7.20.3 Dicerna Oligonucleotide Therapy-based Drug Major Product Offerings
7.20.4 Dicerna Oligonucleotide Therapy-based Drug Revenue in Global Market 2018-2023
7.20.5 Dicerna Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Oligonucleotide Therapy-based Drug Market Opportunities & Trends in Global Market
Table 2. Oligonucleotide Therapy-based Drug Market Drivers in Global Market
Table 3. Oligonucleotide Therapy-based Drug Market Restraints in Global Market
Table 4. Key Players of Oligonucleotide Therapy-based Drug in Global Market
Table 5. Top Oligonucleotide Therapy-based Drug Players in Global Market, Ranking by Revenue 2022
Table 6. Global Oligonucleotide Therapy-based Drug Revenue by Companies, US$, Mn, 2018-2023
Table 7. Global Oligonucleotide Therapy-based Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Oligonucleotide Therapy-based Drug Product Type
Table 9. List of Global Tier 1 Oligonucleotide Therapy-based Drug Companies, Revenue US$, Mn in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Oligonucleotide Therapy-based Drug Companies, Revenue US$, Mn in 2022 and Market Share
Table 11. By Type – Global Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2022 & 2029
Table 12. By Type - Oligonucleotide Therapy-based Drug Revenue in Global US$, Mn, 2018-2023
Table 13. By Type - Oligonucleotide Therapy-based Drug Revenue in Global US$, Mn, 2024-2029
Table 14. By Application – Global Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2022 & 2029
Table 15. By Application - Oligonucleotide Therapy-based Drug Revenue in Global US$, Mn, 2018-2023
Table 16. By Application - Oligonucleotide Therapy-based Drug Revenue in Global US$, Mn, 2024-2029
Table 17. By Region – Global Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2022 & 2029
Table 18. By Region - Global Oligonucleotide Therapy-based Drug Revenue US$, Mn, 2018-2023
Table 19. By Region - Global Oligonucleotide Therapy-based Drug Revenue US$, Mn, 2024-2029
Table 20. By Country - North America Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2023
Table 21. By Country - North America Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2024-2029
Table 22. By Country - Europe Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2023
Table 23. By Country - Europe Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2024-2029
Table 24. By Region - Asia Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2023
Table 25. By Region - Asia Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2024-2029
Table 26. By Country - South America Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2023
Table 27. By Country - South America Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2024-2029
Table 28. By Country - Middle East & Africa Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2023
Table 29. By Country - Middle East & Africa Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2024-2029
Table 30. Sarepta Therapeutics Company Summary
Table 31. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Offerings
Table 32. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 33. Sarepta Therapeutics Key News & Latest Developments
Table 34. Ionis Pharmaceuticals Company Summary
Table 35. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offerings
Table 36. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 37. Ionis Pharmaceuticals Key News & Latest Developments
Table 38. Alnylam Company Summary
Table 39. Alnylam Oligonucleotide Therapy-based Drug Product Offerings
Table 40. Alnylam Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 41. Alnylam Key News & Latest Developments
Table 42. Biogen Company Summary
Table 43. Biogen Oligonucleotide Therapy-based Drug Product Offerings
Table 44. Biogen Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 45. Biogen Key News & Latest Developments
Table 46. Nippon Shinyaku Company Summary
Table 47. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Offerings
Table 48. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 49. Nippon Shinyaku Key News & Latest Developments
Table 50. Sobi Company Summary
Table 51. Sobi Oligonucleotide Therapy-based Drug Product Offerings
Table 52. Sobi Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 53. Sobi Key News & Latest Developments
Table 54. Novartis Company Summary
Table 55. Novartis Oligonucleotide Therapy-based Drug Product Offerings
Table 56. Novartis Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 57. Novartis Key News & Latest Developments
Table 58. BioNTech Company Summary
Table 59. BioNTech Oligonucleotide Therapy-based Drug Product Offerings
Table 60. BioNTech Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 61. BioNTech Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Oligonucleotide Therapy-based Drug Product Offerings
Table 64. Pfizer Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 65. Pfizer Key News & Latest Developments
Table 66. Moderna Therapeutics Company Summary
Table 67. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Offerings
Table 68. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 69. Moderna Therapeutics Key News & Latest Developments
Table 70. Jazz Pharmaceuticals Company Summary
Table 71. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Offerings
Table 72. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 73. Jazz Pharmaceuticals Key News & Latest Developments
Table 74. CureVac Company Summary
Table 75. CureVac Oligonucleotide Therapy-based Drug Product Offerings
Table 76. CureVac Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 77. CureVac Key News & Latest Developments
Table 78. Regulus Therapeutics Company Summary
Table 79. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Offerings
Table 80. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 81. Regulus Therapeutics Key News & Latest Developments
Table 82. ProQR Company Summary
Table 83. ProQR Oligonucleotide Therapy-based Drug Product Offerings
Table 84. ProQR Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 85. ProQR Key News & Latest Developments
Table 86. Secarna Company Summary
Table 87. Secarna Oligonucleotide Therapy-based Drug Product Offerings
Table 88. Secarna Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 89. Secarna Key News & Latest Developments
Table 90. MiNA Therapeutics Company Summary
Table 91. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Offerings
Table 92. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 93. MiNA Therapeutics Key News & Latest Developments
Table 94. Sylentis Company Summary
Table 95. Sylentis Oligonucleotide Therapy-based Drug Product Offerings
Table 96. Sylentis Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 97. Sylentis Key News & Latest Developments
Table 98. Arrowhead Company Summary
Table 99. Arrowhead Oligonucleotide Therapy-based Drug Product Offerings
Table 100. Arrowhead Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 101. Arrowhead Key News & Latest Developments
Table 102. Silence Therapeutics Company Summary
Table 103. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Offerings
Table 104. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 105. Silence Therapeutics Key News & Latest Developments
Table 106. Dicerna Company Summary
Table 107. Dicerna Oligonucleotide Therapy-based Drug Product Offerings
Table 108. Dicerna Oligonucleotide Therapy-based Drug Revenue US$, Mn & 2018-2023
Table 109. Dicerna Key News & Latest Developments
List of Figures
Figure 1. Oligonucleotide Therapy-based Drug Segment by Type in 2022
Figure 2. Oligonucleotide Therapy-based Drug Segment by Application in 2022
Figure 3. Global Oligonucleotide Therapy-based Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Oligonucleotide Therapy-based Drug Market Size: 2022 VS 2029 US$, Mn
Figure 6. Global Oligonucleotide Therapy-based Drug Revenue, 2018-2029 US$, Mn
Figure 7. The Top 3 and 5 Players Market Share by Oligonucleotide Therapy-based Drug Revenue in 2022
Figure 8. By Type - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 9. By Application - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 10. By Type - Global Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2022 & 2029
Figure 11. By Type - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 12. By Application - Global Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2022 & 2029
Figure 13. By Application - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 14. By Region - Global Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 15. By Country - North America Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 16. US Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 17. Canada Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 18. Mexico Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 19. By Country - Europe Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 20. Germany Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 21. France Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 22. U.K. Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 23. Italy Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 24. Russia Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 25. Nordic Countries Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 26. Benelux Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 27. By Region - Asia Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 28. China Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 29. Japan Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 30. South Korea Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 31. Southeast Asia Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 32. India Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 33. By Country - South America Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 34. Brazil Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 35. Argentina Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 36. By Country - Middle East & Africa Oligonucleotide Therapy-based Drug Revenue Market Share, 2018-2029
Figure 37. Turkey Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 38. Israel Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 39. Saudi Arabia Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 40. UAE Oligonucleotide Therapy-based Drug Revenue, US$, Mn, 2018-2029
Figure 41. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 42. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 43. Alnylam Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 44. Biogen Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 45. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 46. Sobi Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 47. Novartis Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 48. BioNTech Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 49. Pfizer Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 50. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 51. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 52. CureVac Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 53. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 54. ProQR Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 55. Secarna Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 56. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 57. Sylentis Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 58. Arrowhead Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 59. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023
Figure 60. Dicerna Oligonucleotide Therapy-based Drug Revenue Year Over Year Growth US$, Mn & 2018-2023

Choose License Type









  Enquire Before Purchase

Have A Question ?
  Email Us


Custom Research

Still haven't found what you're looking for ?
Speak to our Custom Research Team

  Learn More

Why ProspectResearch Reports

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays



ProspectResearch Reports Logo

What our clients say